Pembrolizumab plus lenvatinib in recurrent gynaecological clear cell carcinoma (LARA): a multicentre, single-arm, phase 2 trial.
- DOI
- 10.1016/s1470-2045(25)00662-x
- Published
- 2026 Feb
- Container
- The Lancet. Oncology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/s1470-2045-25-00662-x,
title = {Pembrolizumab plus lenvatinib in recurrent gynaecological clear cell carcinoma (LARA): a multicentre, single-arm, phase 2 trial.},
author = {Ngoi NYL and Lee JY and Lim D and Thian YL and Lim YW and Chan JJ and Chay WY and Zhang Z and Gopinathan A and Lim SE and Low J and Ng J and Tong P and Lee YJ and Park J and Kim JW and Tan TZ and Zhu J and Tai BC and Choi CH and Kim BG and Tan DSP},
year = {2026},
journal = {The Lancet. Oncology},
doi = {10.1016/s1470-2045(25)00662-x},
url = {https://doi.org/10.1016/s1470-2045(25)00662-x}
}RIS
TY - JOUR TI - Pembrolizumab plus lenvatinib in recurrent gynaecological clear cell carcinoma (LARA): a multicentre, single-arm, phase 2 trial. AU - Ngoi NYL AU - Lee JY AU - Lim D AU - Thian YL AU - Lim YW AU - Chan JJ AU - Chay WY AU - Zhang Z AU - Gopinathan A AU - Lim SE AU - Low J AU - Ng J AU - Tong P AU - Lee YJ AU - Park J AU - Kim JW AU - Tan TZ AU - Zhu J AU - Tai BC AU - Choi CH AU - Kim BG AU - Tan DSP PY - 2026 JO - The Lancet. Oncology DO - 10.1016/s1470-2045(25)00662-x UR - https://doi.org/10.1016/s1470-2045(25)00662-x ER -
APA
NYL, N., JY, L., D, L., YL, T., YW, L., JJ, C., WY, C., Z, Z., A, G., SE, L., J, L., J, N., P, T., YJ, L., J, P., JW, K., TZ, T., J, Z., BC, T., CH, C., BG, K., & DSP, T. (2026). Pembrolizumab plus lenvatinib in recurrent gynaecological clear cell carcinoma (LARA): a multicentre, single-arm, phase 2 trial.. The Lancet. Oncology. https://doi.org/10.1016/s1470-2045(25)00662-x
Source records
- pubmed · retrieved 2026-09-26T07:45:48.368Z